Low‐Dose Versus High‐Dose Lenvatinib in Radioiodine Refractory Differentiated Thyroid Cancer—A Real‐World Safety and Efficacy Analysis
The study suggests that starting with lower doses of lenvatinib, followed by dose escalation if tolerated, may offer a safer approach with significantly lower rates of drug interruptions and dose reductions, with comparable efficacy in RR-DTC patients. Further validation by larger prospective trials is warranted.
Authors
- Swayamjeet Satapathy (ORCID: https://orcid.org/0000-0001-5318-6644)
- Madhavi Tripathi (ORCID: https://orcid.org/0000-0003-1033-1690)
- Chandrasekhar Bal (ORCID: https://orcid.org/0000-0003-4378-5584)
- Shubha Gadde Ravindra
- Kunal Ramesh Chandekar (ORCID: https://orcid.org/0009-0007-3599-0322)
- G B Priyanka
- Sanjana Ballal
- Jeepalem Sai Moulika
Institutions
- All India Institute of Medical Sciences (IN)
Publication Details
- Journal
- Clinical Endocrinology
- Published
- 2025-02-04
- DOI
- https://doi.org/10.1111/cen.15214
- Citations
- 4
- Primary Topic
- Thyroid Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 5.18